2-butyl-6-methylpyrimidin-4(3H)-one | 90565-51-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-butyl-6-methylpyrimidin-4(3H)-one
• 英文别名: 2-butyl-4-methyl-1,6-dihydro-6-pyrimidone；2-n-butyl-6-methylpyrimidin-4(3H)-one；2-butyl-6-methyl-3H-pyrimidin-4-one；2-Butyl-6-methyl-3H-pyrimidin-4-on；2-butyl-6-methyl-1H-pyrimidin-4-one
• CAS: 90565-51-8
• 化学式: C₉H₁₄N₂O
• 分子量: 166.223
• InChiKey: HEFURGIWSUMDFP-UHFFFAOYSA-N

物化性质

• 熔点：
  120 °C
• 沸点：
  256.0±23.0 °C(Predicted)
• 密度：
  1.08±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-butyl-6-methylpyrimidin-4(3H)-one 在 甲醇 、 Lindlar's catalyst 、 三氯氧磷 作用下， 生成 2-butyl-4-methyl-pyrimidine
  参考文献：
  名称：

  Yanai; Naito, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1941, vol. 61, p. 99,105; dtsch. Ref. S. 46, 52

  摘要：

  DOI：
• 作为产物：
  描述：

  N-(3-oxobutanoyl)pentanamide 在 ammonium acetate 作用下， 以 溶剂黄146 为溶剂， 反应 0.25h， 以92%的产率得到2-butyl-6-methylpyrimidin-4(3H)-one
  参考文献：
  名称：

  A facile synthesis of pyrimidin-4-ones

  摘要：

  A facile synthesis of 2,6-disubstituted pyrimidin-4-ones and 2,5,6-trisubstituted pyrimidin-4-ones from commercially available materials with application of microwave technology in key steps is described. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2009.11.096

文献信息

• N-3-Substituted Pyrimidinones as Potent, Orally Active, AT1 Selective Angiotensin II Receptor Antagonists
  作者：Aldo Salimbeni、Renato Canevotti、Fabio Paleari、Davide Poma、Saturnino Caliari、Francesco Fici、Rocco Cirillo、Anna R. Renzetti、Alessandro Subissi

  DOI：10.1021/jm00024a008

  日期：1995.11

  A novel series of nonpeptide angiotensin II (A II) antagonists containing a pyrimidinone ring which carries a C-linked biphenyltetrazole moiety and a carboxyheteroaryl group on the 3-position have been prepared. Their affinity for the AT1 receptor was determined in a binding assay on rat adrenal cortical membranes. The in vivo antihypertensive properties were tested by evaluating the inhibition of

  制备了一系列新的非肽血管紧张素II（A II）拮抗剂，该拮抗剂包含嘧啶酮环，该嘧啶酮环在3位上带有C连接的联苯四唑部分和羧基杂芳基。通过对大鼠肾上腺皮质膜的结合试验确定它们对AT1受体的亲和力。通过评估对A II的升压反应的抑制，然后进行静脉和内服给药，来测试体内的抗高血压特性。与其他已知的A II拮抗剂（例如DUP）相比，广泛的分子建模研究（包括分子静电势分布的比较，构象分析和A II计算药效团模型上的覆盖物）用于评估新化合物的结构参数。 -753和SK＆F 108566）。根据建模研究，在嘧啶酮环的3-位引入（羧基杂芳基）甲基部分导致衍生物的效力增加。甲基2-[[[4-丁基-2-甲基-6-氧代-5-] [[2'-（1H-四唑-5-基）] [1,1'-联苯] -4-基]甲基] -1 -（6H）-嘧啶基]甲基] -3-噻吩羧酸酯（3k，LR-B / 081），是该系列中最有效的化合物之一（Ki
• Substituted pyrimidinones as angiotensin II antagonists
  申请人：Merck & Co., Inc.

  公开号：US05100897A1

  公开（公告）日：1992-03-31

  Novel substituted pyrimidinones of formula (I) which are useful as angiotensin II antagonists, are disclosed. ##STR1##

  公开了作为血管紧张素II拮抗剂有用的式(I)的新型取代嘧啶酮。
• Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives
  作者：Gurram R Madhavan、Ranjan Chakrabarti、Reeba K Vikramadithyan、Rao N.V.S Mamidi、V Balraju、B.M Rajesh、Parimal Misra、Sunil K.B Kumar、Braj B Lohray、Vidya B Lohray、Ramanujam Rajagopalan

  DOI：10.1016/s0968-0896(02)00107-4

  日期：2002.8

  A series of pyrimidinone derivatives of thiazolidinediones were synthesized. Their biological activity were evaluated in insulin resistant, hyperglycemic and obese db/db mice. In vitro PPARgamma transactivation assay was performed in HEK 293T cells. PMT13 showed the best biological activity in this series. PMT13 (5-[4-[2-[2-ethyl-4-methyl-6-oxo-1,6-dihydro-1-pyrimidinyl]ethoxy]phenylmethyl]thiazolidine-2

  合成了一系列噻唑烷二酮的嘧啶酮衍生物。在胰岛素抵抗，高血糖和肥胖的db / db小鼠中评估了它们的生物学活性。在HEK 293T细胞中进行了体外PPARγ激活测定。PMT13在该系列中表现出最好的生物活性。PMT13（5- [4- [2- [2-乙基-4-甲基-6-氧代-1,6-二氢-1-嘧啶基]乙氧基]苯基甲基]噻唑烷-2,4-二酮）血浆葡萄糖水平更高， db / db小鼠的甘油三酸酯和胰岛素降低活性高于罗格列酮和吡格列酮。PMT13显示出比标准化合物更好的PPARγ反式激活。Wistar大鼠的药代动力学研究表明，PMT13具有良好的全身性暴露。在Wistar大鼠中进行的28天口服毒性研究未显示任何与治疗相关的不良反应。
• Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
  申请人：Dr. Reddy's Research Foundation

  公开号：US06310069B1

  公开（公告）日：2001-10-30

  The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.

  本发明涉及新型抗糖尿病化合物及其互变异构体、衍生物、立体异构体、多晶形态、药用可接受盐、药用可接受溶剂和含有它们的药用可接受组合物。本发明特别涉及一般式(I)的新型噁唑烷二酮衍生物及其药用可接受盐、药用可接受溶剂和含有它们的药用组合物。
• Heterocyclic compounds, process for their preparation and pharmaceutical
  申请人：Dr. Reddy's Research Foundation

  公开号：US05885997A1

  公开（公告）日：1999-03-23

  The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. ##STR1##

  本发明涉及新型抗糖尿病化合物，它们的互变异构形式，它们的衍生物，它们的立体异构体，它们的多晶形态，它们的药学上可接受的盐，它们的药学上可接受的溶剂合物以及含有它们的药学上可接受的组合物。本发明特别涉及一般式（I）的新型噁唑烷二酮衍生物，以及它们的药学上可接受的盐、药学上可接受的溶剂和含有它们的药用组合物。

表征谱图